Orexin-A

Orexin-A is one of a pair of excitatory neuropeptides, the orexins, which are also called hypocretins ^[1][3]. Both orexin-A and its partner orexin-B are produced from the same larger precursor protein, prepro-orexin, which is cut by enzymes into the two finished peptides ^[1]. Orexin-A is a chain of 33 amino acids held in a compact shape by two disulfide bonds between cysteine residues, a structure that distinguishes it from the shorter, linear orexin-B ^[1][3]. The two names reflect research teams that described the system at nearly the same time: one called the peptides orexins for their appetite-stimulating effect, the other called them hypocretins for their hypothalamic origin ^[3].

The peptide is made by a relatively small group of neurons clustered in the lateral and posterior hypothalamus, a deep brain region involved in basic drives ^[1]. Despite their small number, these neurons send projections throughout the brain and spinal cord, reaching and exciting the arousal systems that use dopamine, noradrenaline, histamine, and acetylcholine ^[2]. Through these wide connections orexin-A helps knit together signals about metabolism, time of day, and the accumulated need for sleep ^[2].

Orexin-A is best known for stabilizing wakefulness and preventing unwanted transitions between waking and sleep ^[2][3]. It also stimulates appetite and feeding, influences energy expenditure, and takes part in circuits tied to motivation and reward ^[1]. The system's importance became clear through narcolepsy type 1, a disorder marked by irresistible daytime sleepiness and sudden loss of muscle tone, which is caused by the destruction of orexin-producing neurons, most likely through an autoimmune process ^[4]. Measuring orexin-A in the cerebrospinal fluid, where it is very low or absent in this form of narcolepsy, is used in diagnosis ^[4]. These findings have driven interest in drugs that either block or mimic orexin signaling ^[3].

Understanding of orexin-A has reshaped the treatment of sleep disorders. Medicines that block orexin receptors, known as orexin receptor antagonists, promote sleep and are approved for insomnia, beginning with suvorexant in 2014 and followed by lemborexant and daridorexant ^[3]. Conversely, compounds that activate orexin receptors are being developed to treat narcolepsy and other conditions of excessive sleepiness ^[3]. Orexin-A itself is chiefly a research substance and an endogenous signaling molecule rather than a marketed drug, though experimental delivery, including through the nose, has been explored as a way to boost alertness ^[3].

Human safety data is thin and mostly from small intranasal studies in narcolepsy, where no clear harmful effects were reported in the short term. Being an arousal peptide, the obvious cautions are overstimulation, jitteriness, and wrecked sleep if used late, plus possible bumps in blood pressure or heart rate since orexin signaling touches sympathetic tone. It is poorly characterized in healthy people over any real length of time, so it sits firmly in research and reference territory rather than being a supplement.

Orexin-A was discovered in 1998 by two independent research groups working almost simultaneously, a coincidence that left the molecule with two names. One team, led by Takeshi Sakurai and Masashi Yanagisawa, identified a pair of hypothalamic peptides that stimulated feeding and named them orexins after the Greek word for appetite; the other, led by Luis de Lecea and Gregor Sutcliffe, described the same peptides from a hypothalamus-enriched cDNA and called them hypocretins. Orexin-A, or hypocretin-1, is a 33-amino-acid peptide cleaved from a shared precursor and produced by a small cluster of neurons in the lateral hypothalamus.

Within two years the field pivoted from feeding to sleep, when researchers showed that disruption of orexin signaling caused narcolepsy in dogs and mice, and that people with narcolepsy type 1 had lost their orexin neurons. That insight reframed narcolepsy as an orexin-deficiency disease and made the orexin system one of the most actively pursued targets in modern sleep medicine, culminating in orexin-2 receptor agonists now advancing through clinical trials as replacement-style therapy.

Orexin-A holds an almost singular place in neuroscience as the master switch that stabilizes wakefulness, and its story is one of the clearest examples of a single molecule explaining a disease: the selective loss of orexin neurons is essentially the cause of narcolepsy type 1. That clarity has made it enormously compelling to researchers, because restoring orexin signaling promises a mechanism-based treatment rather than a symptomatic stimulant, and orexin-2 receptor agonists modeled on its action have shown striking wake-promoting effects in early human trials.

As a peptide, orexin-A itself faces the practical limits familiar to peptide therapeutics, including poor oral availability and difficulty crossing into the brain, which is why drug developers have largely pursued small-molecule agonists and why the native peptide is used mainly as a research and investigational tool. Its scientific importance, however, is beyond dispute, and few discoveries have so rapidly reshaped an entire field of medicine as the orexins did after 1998.